Collegium Pharmaceutical Inc

In Stage 2 advancing, COLL has pulled back into the rising 9/21/50 EMA zone and is holding above these EMAs with neutral momentum readings, presenting a favorable buy entry. Medium- and long-term biases remain bullish, supported by higher-highs and higher-lows structure and an intact uptrend above the 200 DMA. Execution is to buy now on this pullback, while monitoring EMA support integrity and overhead resistance at the 200 DMA.

• ↑Q1 net product revenues rose 9% YoY to $193.5M; Jornay PM guidance of $190–$200M implies 31% growth
• ↑Astaris acquisition expected to contribute ~$50M in H2 net revenues plus >$50M in synergies
• ↓Operating expenses climbed 80% YoY to $75.6M, pressuring margins and profitability